[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.176.252. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
January 5, 2016

Valsartan/Sacubitril for Heart FailureReconciling Disparities Between Preclinical and Clinical Investigations

Author Affiliations
  • 1Departments of Medicine and Physiology, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
  • 2Wills Eye Institute, Philadelphia, Pennsylvania
  • 3Thomas Jefferson University, Philadelphia, Pennsylvania
  • 4Department of Neurology, McKnight Brain Institute, University of Florida College of Medicine, Gainesville
JAMA. 2016;315(1):25-26. doi:10.1001/jama.2015.17632

Valsartan/sacubitril (Entresto, Novartis) is a combination of the neprilysin inhibitor sacubitril and the angiotensin receptor antagonist valsartan. In July 2015, the US Food and Drug Administration (FDA) approved valsartan/sacubitril through the fast-track pathway for the treatment of patients with New York Heart Association class II through IV heart failure symptoms and a reduced ejection fraction. The approval was based on the results of a single phase 3 clinical trial (PARADIGM-HF)1 that included 8400 patients. In this trial, valsartan/sacubitril was associated with a 20% (hazard ratio, 0.80) decrease in the primary end point of death from cardiovascular cause or first hospitalization for heart failure (from 26.5% to 21.8%), when compared with the angiotensin-converting inhibitor enalapril, and a 16% (hazard ratio, 0.84) reduction in all-cause mortality (from 19.8% to 17.0%). However, recent translational science studies involving the central nervous system and the eye suggest that other effects of valsartan/sacubitril might influence its use in some patients.

First Page Preview View Large
First page PDF preview
First page PDF preview
×